NASDAQ · PRVA
Healthcare · Medical - Healthcare Information Services
$20.28
Up+$0.02 (+0.10%)
Updated Oct 8, 2026, 1:56 AM
SID Score
4.0/10
Composite research score
Smart Money
58/100
Neutral
Price performance · PRVA
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
PRVA closed at $20.28 after 20 trading sessions, down 0.69% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $20.64 | $20.88 | $20.26 | $20.28 | 1.08M |
| Oct 5, 2026 | $20.37 | $20.545 | $20.215 | $20.45 | 1.34M |
| Oct 2, 2026 | $20.27 | $20.325 | $19.96 | $20.30 | 1.28M |
| Oct 1, 2026 | $19.73 | $20.38 | $19.49 | $20.03 | 1.41M |
| Sep 30, 2026 | $19.73 | $20.05 | $19.505 | $19.69 | 1.34M |
| Sep 29, 2026 | $19.77 | $19.77 | $19.27 | $19.62 | 998.68K |
| Sep 28, 2026 | $19.67 | $20.12 | $19.50 | $19.87 | 1.4M |
| Sep 25, 2026 | $19.36 | $19.88 | $19.28 | $19.71 | 1.39M |
| Sep 24, 2026 | $19.10 | $19.40 | $18.915 | $19.39 | 1.48M |
| Sep 23, 2026 | $19.39 | $19.535 | $18.975 | $19.10 | 980.09K |
| Sep 22, 2026 | $19.53 | $19.9001 | $19.425 | $19.46 | 1.09M |
| Sep 21, 2026 | $19.86 | $20.45 | $19.42 | $19.54 | 980.24K |
| Sep 18, 2026 | $19.95 | $20.165 | $19.761 | $19.85 | 2.76M |
| Sep 17, 2026 | $20.50 | $20.66 | $20.03 | $20.09 | 1.14M |
| Sep 16, 2026 | $20.43 | $20.65 | $20.11 | $20.37 | 1.41M |
| Sep 15, 2026 | $20.89 | $20.89 | $20.24 | $20.36 | 1.23M |
| Sep 14, 2026 | $20.61 | $21.09 | $20.61 | $20.88 | 1.37M |
| Sep 11, 2026 | $20.61 | $20.695 | $20.28 | $20.42 | 925.3K |
| Sep 10, 2026 | $20.42 | $20.9799 | $20.23 | $20.37 | 1.26M |
| Sep 9, 2026 | $20.55 | $20.58 | $20.165 | $20.42 | 1.04M |
The latest Smart Investors Daily articles mentioning PRVA.
Company
Market Activity
Research & News
PRVA research
Company profile and research snapshot.
Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 26, 2026 | Barclays | Equal-Weight | — |
| May 8, 2026 | Canaccord Genuity | Buy | — |
| Apr 8, 2026 | Evercore ISI Group | Outperform | — |
| Mar 25, 2026 | Barclays | Equal-Weight | — |
| Mar 3, 2026 | Citigroup | Buy | — |
Generated Oct 7, 2026, 9:12 PM
Privia Health Group (PRVA) is essentially unchanged, moving just $0.02 higher in modest trading activity. The muted price action reflects a lack of significant new catalysts, with the company's Q2 2026 earnings call transcript now available for investor review alongside general market skepticism about sub-$50 healthcare stocks.
Bottom line: PRVA's flat performance reflects a lack of immediate catalysts and lingering skepticism from some analyst circles about sub-$50 healthcare valuations. Investors should closely review the Q2 2026 earnings call transcript for evidence of margin improvement and pathway to profitability, as these metrics will likely determine whether the stock attracts renewed buying interest or faces continued pressure.
Yahoo · Oct 5, 2026
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
Benzinga · Oct 5, 2026
Privia Health Gr (NASDAQ:PRVA) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts
Yahoo · Sep 30, 2026
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.
Yahoo · Sep 19, 2026
Activists recently filed disclosures with the SEC that included Privia Health Group (PRVA), putting fresh attention on the physician-enablement specialist and how its shares trade around the latest ownership updates. At around US$19.85 per share, Privia Health Group has been under pressure, with the share price falling 6.4% over the past month and 16.1% over the last quarter. The 1-year total shareholder return is down 11.3%, pointing to fading momentum that may reflect investors reassessing...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PRVA.
